Exaggeration of treatment benefits using the “event-based” number needed to treat

Shawn D. Aaron MD, Dean A. Fergusson PhD

Recently, several articles have been published that advocate an alternative method for calculating the number needed to treat to assess the effects of medications in clinical trials.1 This new method, which gives an “event-based” number needed to treat, calculates the number needed to treat based on outcomes that can occur more than once in the same patient, instead of dichotomous outcomes that only occur once in each patient during a given period.

The number needed to treat is traditionally defined as the reciprocal of the absolute risk reduction. It was originally meant to be calculated for dichotomous events (e.g., death, myocardial infarction) that occurred once in each patient during a particular period.3 The number needed to treat can also be applied to continuous or ordinal outcomes if the outcome can be dichotomized into 2 discrete categories (e.g., the proportion of patients who attain the expected minimal clinically important difference in the outcome).5 The number needed to treat represents the estimated number of patients who need to receive a treatment, compared to a control, for 1 additional patient to benefit. An example of how to calculate a traditional number needed to treat is shown in Box 1.

An alternative approach: the “event-based” number needed to treat

Recent studies have described an alternative method for calculating the number needed to treat.1 Studies that use this method define the event-based number needed to treat as “the reciprocal of the difference between the treatment and control groups in the rate of a particular outcome per patient within a given time frame.” This definition is intended to be applied to recurrent events, such as exacerbations of chronic obstructive pulmonary disease. The rate of events per patient-year is calculated for the treatment and control groups. The reciprocal of the difference in rates is used to calculate an event-based number needed to treat.1,2

Since being introduced into the medical literature in 2005,1 the event-based number needed to treat has been used extensively to describe results of respiratory clinical trials. In a recent clinical trial, Kardos and colleagues found that the rate of exacerbations of chronic obstructive pulmonary disease was 0.92 per patient per year among patients randomly assigned to treatment with fluticasone and salmeterol, and 1.4 per patient per year among those randomly assigned to receive salmeterol alone.1 The authors calculated the number needed to treat to be 2.08 (1 ÷ [1.4–0.92]). They therefore stated that the number of patients needed to treat with fluticasone and salmeterol rather than salmeterol alone to prevent 1 exacerbation of chronic obstructive pulmonary disease per year was 2.08. Similarly, the recently published Towards a Revolution in COPD Health (TORCH) trial observed an annual rate of exacerbations of 0.85 in the fluticasone and salmeterol group and 1.13 in the placebo group. The authors calculated a number needed to treat of 4 (1 ÷ [1.13–0.85]), implying that 4 additional patients need to receive fluticasone and salmeterol to prevent 1 exacerbation over 1 year.2 The event-based number needed to treat has also been used to describe the effects of nonpharmacologic interventions for chronic obstructive pulmonary disease, such as nurse-led intermediate care programs for prevention of unscheduled physician visits.3,4

False exaggerations of treatment benefits

Unfortunately, the above method for calculating the number needed to treat may be misleading because the number needed to treat as used in this context has no theoretical foundation. This number cannot be correctly applied to recurring events in the same patient (such as exacerbations of chronic obstructive pulmonary disease) because a summation of these individual events does not follow a binary distribution.

In fact, in clinical trials, as in real life, a large proportion of patients will have no exacerbations of chronic obstructive pulmonary disease in 1 year, some patients will have 1 or 2 exacerbations and a few patients will experience multiple exacerbations. Consider the example outlined in Table 1 where 10 patients are randomly assigned to placebo for 1 year and 10 patients

Key points

- The number-needed-to-treat statistic has been used for years in clinical medicine.
- It is traditionally calculated as the reciprocal of the absolute risk reduction.
- The “event-based” number needed to treat is meant to be applied to recurrent events, such as exacerbations of chronic obstructive pulmonary disease.
- The event-based number needed to treat may be misleading because it is heavily influenced by a minority of patients who experience multiple recurrent events.
- Use of the number needed to treat for recurrent events may provide results that falsely exaggerate the beneficial effects of treatments in clinical trials.

Shawn Aaron and Dean Fergusson are with the Ottawa Health Research Institute, University of Ottawa, Ottawa, Ont.

Note: Shawn Aaron and Dean Fergusson are with the Ottawa Health Research Institute, University of Ottawa, Ottawa, Ont.

DOI 10.1503/cmaj.080018

© 2008 Canadian Medical Association or its licensors
are assigned to treatment for 1 year. The treatment is designed to prevent exacerbations of chronic obstructive pulmonary disease. In this example, 1 patient in the placebo group experiences a single exacerbation in 1 year, 2 patients experience 6 exacerbations and the remaining patients have none. In total, patients in the placebo group experienced 13 exacerbations over 10 patient-years, or 1.3 exacerbations per patient-year. In contrast, in the treatment group, 1 patient has 3 exacerbations and 1 patient has 5. The remaining patients have none. In total, patients in the treatment group experienced 8 exacerbations and the remaining patients have none. In total, patients in the placebo group experienced 13 exacerbations over 10 patient-years, or 1.7 exacerbations per patient-year. In contrast, in the treatment group, 1 patient has 3 exacerbations and the remaining patients have none. In total, patients in the placebo group have experienced 17 exacerbations over 10 patient-years, or 1.7 exacerbations per patient-year. In contrast, 2 patients in the treatment group each experience 2 exacerbations and the rest have none. In total, patients in the treatment group experience 4 exacerbations over 10 patient-years, or 0.4 exacerbations per patient-year. The event-based number needed to treat in this example is 0.77 (1 ÷ [1.7–0.4]). This suggests that 0.77 patients would have to receive treatment to prevent a single exacerbation. Clearly it is impossible for 0.77 of a patient to receive treatment. Thus, this statistic has no legitimate clinical interpretation. If the number needed to treat of 0.77 is rounded to 1, it implies that treatment is indicated for every patient because treatment would prevent exacerbations for all patients. Review of the actual data indicates that clearly this is not the case, because 70% of patients

**Box 1: Calculation of the traditional and event-based number needed to treat**

**Traditional**

Consider a clinical trial with 100 patients randomly assigned to treatment A for 1 year and 100 patients assigned to treatment B:

- Group A: 30% of patients die within 1 year.
- Group B: 10% of patients die within 1 year.
- The absolute risk reduction for death is 30% – 10% = 20%, or 0.20.
- The number needed to treat with treatment B, rather than treatment A, to prevent 1 additional death during the 1-year period is the reciprocal of the absolute risk reduction.
- The traditional number needed to treat is 5 (1 ÷ 0.20).

**Event-based**

Consider a clinical trial where 100 patients with chronic obstructive pulmonary disease are randomly assigned to treatment A for 1 year and 100 patients assigned to treatment B. Instead of death, the outcome for this trial is exacerbations of chronic obstructive pulmonary disease.

- Group A: 50 patients have 0 exacerbations, 30 patients have 1 exacerbation, and 20 patients have 2 exacerbations.
- Patients in group A have 70 exacerbations over 100 patient-years = 0.7 exacerbations per patient-year.
- Group B: In group B, 50 patients have 0 exacerbations, 30 patients have 1 exacerbation, and 20 patients have 5 exacerbations.
- Patients in group B have 130 exacerbations over 100 patient-years = 1.3 exacerbations per patient-year.
- The event-based number needed to treat is the reciprocal of the difference in rates and is 1.67 (1 ÷ [1.3–0.7]).

**Table 1: An example calculation of the traditional and event-based number needed to treat (NNT) for a treatment to prevent exacerbations of chronic obstructive pulmonary disease**

| Patient no. | Placebo | Treatment |
|-------------|---------|-----------|
| 1           | 0       | 0         |
| 2           | 0       | 0         |
| 3           | 0       | 0         |
| 4           | 0       | 0         |
| 5           | 0       | 0         |
| 6           | 0       | 0         |
| 7           | 0       | 0         |
| 8           | 1       | 0         |
| 9           | 6       | 3         |
| 10          | 6       | 5         |
| **Total**   | **13**  | **8**     |

**Annual rate of exacerbations per patient-year**

|                | Placebo | Treatment |
|----------------|---------|-----------|
| (13 exacerbations /10 patient-years) | 1.3     | 0.8       |

**Traditional NNT**

1 ÷ (0.3 – 0.2) = 10

**Event-based NNT**

1 ÷ (1.3 – 0.8) = 2
in this example would not experience any benefit of treatment. Again, the event-based number needed to treat provides misleading information.

Instead, the number needed to treat should be calculated based on the difference in the proportion of patients who experience 1 or more exacerbations during the trial period. An example of the correct use of the number needed to treat statistic to describe exacerbations of chronic obstructive pulmonary disease can be taken directly from previous clinical trials. As described in the trial by Kardos and colleagues, 241 of 487 (49.5%) patients who received salmeterol and 210 of 507 (41.4%) patients who received salmeterol and fluticasone had at least 1 exacerbation during the 44 week trial. Therefore, the absolute risk reduction was 8.1% (49.5%–41.4%). The number needed to treat for salmeterol and fluticasone (rather than salmeterol alone) to prevent 1 additional patient from experiencing an exacerbation in 44 weeks was 12.3 (1 ÷ 0.081). The traditional number needed to treat of 12.3 is much greater than the event-based number needed to treat of 2.0 reported by the Kardos and colleagues.11

Conclusion

The number needed to treat can be applied with confidence to binary outcomes such as mortality rates. It can also be applied to continuous or ordinal outcomes that can be dichotomized. However, the number needed to treat should be interpreted with caution if it is applied to recurrent events that occur in the same patients over time. In this situation, the number needed to treat may be misleading, especially if some patients have many recurrent events and other patients have no events. If applied to recurrent event data, the event-based number needed to treat may lead clinicians to overprescribe therapies based on statistically incorrect and artificially inflated numbers needed to treat.

Application of the event-based number needed to treat has been limited thus far to clinical trials of interventions designed to prevent exacerbations of chronic obstructive pulmonary disease. However, patients with other chronic conditions, such as asthma, multiple sclerosis or sickle cell anemia, also experience recurrent exacerbation events over time. It is likely that the event-based number needed to treat will eventually be applied to these conditions as well. Thus, clinicians need to be aware of the potential for exaggeration of treatment benefits if this statistic is improperly applied.

This article has been peer reviewed.

Contributors: Shawn Aaron wrote the first draft of the manuscript. Both of the authors critically revised the manuscript for important intellectual content and approved the final version submitted for publication.

REFERENCES

1. Halpin D.M.G. Evaluating the effectiveness of combination therapy to prevent COPD exacerbations: the value of NNT analysis. Int J Clin Pract 2005;59:1187-94.
2. Cazzola M. Application of number needed to treat (NNT) as a measure of treatment effect in respiratory medicine. Treat Respir Med 2006;5:79-84.
3. Luscapis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-33.
4. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-4.
5. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998;317:1309-12.
6. Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes. Novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol 2004;61:1066-70.
7. Walter SD. Number needed to treat (NNT): estimation of a measure of clinical benefit. Stat Med 2001;20:3947-62.
8. Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:144-9.
9. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
10. Srithar M, Taylor R, Dowson S, et al. A nurse led intermediate care package in patients who have been hospitalised with an acute exacerbation of chronic obstructive pulmonary disease. Thorax 2008;63:194-200.
11. Aaron S. Avoiding mistakes in calculating the number needed to treat in severe COPD. Am J Respir Crit Care Med 2007;175:1347.

Correspondence to: Dr. Shawn Aaron, The Ottawa Hospital, General Campus, 501 Smyth Rd., Ottawa ON K1H 8L6; fax 613 737-8402; saaron@ohri.ca

For a further discussion about the use and misuse of the number needed to treat, see the Analysis article by Finlay McAlister in the September 9 issue (CMAJ 2008;179:549-53).